Date published: 2026-5-12

1-800-457-3801

SCBT Portrait Logo
Seach Input

MRP-L39 Inhibitors

MRP-L39, also known as Mitochondrial Ribosomal Protein L39, is a critical component of the mitochondrial ribosome, which is responsible for synthesizing proteins essential for mitochondrial function and cellular metabolism. Specifically, MRP-L39 is a structural constituent of the large subunit of the mitochondrial ribosome, where it contributes to the translation of mitochondrial DNA-encoded mRNA into functional proteins within the mitochondrial matrix. Mitochondria play pivotal roles in cellular energy production, apoptosis regulation, and reactive oxygen species (ROS) generation, making proper mitochondrial function essential for cellular homeostasis and overall organismal health. As such, MRP-L39 plays a crucial role in maintaining mitochondrial protein synthesis and function, thereby impacting various cellular processes essential for cellular survival and function. Inhibiting MRP-L39 function is paramount for elucidating its role in mitochondrial protein synthesis and understanding its potential implications in mitochondrial dysfunction-related diseases. General mechanisms of MRP-L39 inhibition may involve disrupting its binding to other ribosomal proteins, interfering with its incorporation into the mitochondrial ribosome, or inhibiting its catalytic activity during protein translation. Pharmacological inhibitors or genetic manipulations targeting MRP-L39 expression or function can be utilized to investigate its specific contributions to mitochondrial protein synthesis and cellular metabolism. Additionally, elucidating the upstream regulatory pathways or post-translational modifications that modulate MRP-L39 activity may provide insights into its inhibition mechanisms and potential targets for mitochondrial diseases associated with aberrant mitochondrial protein synthesis. Overall, unraveling the mechanisms of MRP-L39 inhibition is crucial for advancing our understanding of mitochondrial biology and identifying novel strategies for intervention in mitochondrial dysfunction-related disorders.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Verapamil

52-53-9sc-507373
1 g
$374.00
(0)

Verapamil inhibits MRP-L39 by blocking its transport function, reducing the efflux of various substrates from cells. It does this by binding to calcium channels, indirectly affecting MRP-L39 activity.

Probenecid

57-66-9sc-202773
sc-202773A
sc-202773B
sc-202773C
1 g
5 g
25 g
100 g
$28.00
$39.00
$100.00
$277.00
28
(2)

Probenecid inhibits MRP-L39 by competing with its substrates for binding, thereby reducing the efflux of drugs and toxins from cells. It acts as a competitive inhibitor of MRP-L39 transport.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$138.00
$380.00
101
(4)

Cisplatin induces cross-linking of DNA, leading to cell damage and apoptosis. This indirectly inhibits MRP-L39 by inhibiting the efflux of DNA-damaging agents.

Quinidine

56-54-2sc-212614
10 g
$104.00
3
(1)

Quinidine inhibits MRP-L39 by affecting its ATPase activity, reducing energy supply for drug efflux. It also interferes with MRP-L39 substrate binding.

(±)-Sulfinpyrazone

57-96-5sc-202822
sc-202822A
1 g
5 g
$42.00
$94.00
2
(1)

Sulfinpyrazone inhibits MRP-L39 by competing with substrates for transport, reducing the efflux of drugs and xenobiotics. It acts as a competitive inhibitor.

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
$29.00
$38.00
18
(1)

Indomethacin inhibits MRP-L39 by interfering with its ATPase activity, reducing the energy required for drug efflux. It also affects substrate binding.

MK-571

115103-85-0sc-201340
sc-201340A
5 mg
25 mg
$109.00
$421.00
8
(2)

MK-571 inhibits MRP-L39 by binding to a specific site on the transporter, blocking the efflux of leukotrienes and other substrates.

Nifedipine

21829-25-4sc-3589
sc-3589A
1 g
5 g
$59.00
$173.00
15
(1)

Nifedipine inhibits MRP-L39 by affecting its ATPase activity, reducing energy supply for drug efflux. It also interferes with MRP-L39 substrate binding.

Diclofenac acid

15307-86-5sc-357332
sc-357332A
5 g
25 g
$109.00
$298.00
5
(1)

Diclofenac acid inhibits MRP-L39 by interfering with its ATPase activity and substrate binding, reducing the efflux of various drugs and compounds.

Furosemide

54-31-9sc-203961
50 mg
$41.00
(1)

Furosemide inhibits MRP-L39 by competing with substrates for transport, reducing the efflux of drugs and xenobiotics. It acts as a competitive inhibitor.